Astra Wins MedImmune Auction; $15.6 Billion Price Tag Raises Eyebrows
Executive Summary
AstraZeneca's move to bolster its biologics portfolio through the acquisition of MedImmune for roughly $15.6 billion illustrates the increasingly high stakes of mergers in the biotech space
You may also be interested in...
Farewell To MedImmune: AstraZeneca Will Combine Large And Small Molecule Research
The company will integrate MedImmune, which has operated as the biologics research arm of AstraZeneca, amid an R&D and commercial restructuring.
Deals Of The Week: AstraZeneca/Vanderbilt, Medicago, OcellO/Merus
High-level executive changes at AstraZeneca continue pondering of where the British pharma turns next for growth – will it look to large-scale M&A again?
Infinity Regains Rights To Its Lead Program
Biotech pays nothing upfront to regain the Phase III HSP90 inhibitor, which is still on track in multiple clinical trials.